{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:10Z","timestamp":1790661070008,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anorexia nervosa (AN) is an eating disorder characterized by severe hypophagia and weight loss, and an intense fear of weight gain. Activity-based anorexia (ABA) refers to the weight loss, hypophagia and paradoxical hyperactivity that develops in rodents exposed to running wheels and restricted food access, and provides a model for aspects of AN. The atypical antipsychotic olanzapine was recently shown to reduce both AN symptoms and ABA. We examined which component of the complex pharmacological profile of olanzapine reduces ABA. Mice received 5-HT<jats:sub>2A\/2C<\/jats:sub>, 5-HT<jats:sub>3<\/jats:sub>, dopamine D<jats:sub>1<\/jats:sub>-like, D<jats:sub>2<\/jats:sub>, D<jats:sub>3<\/jats:sub>or D<jats:sub>2\/3<\/jats:sub>antagonist treatment, and were assessed for food intake, body weight, wheel running and survival in ABA. D<jats:sub>2\/3<\/jats:sub>receptor antagonists eticlopride and amisulpride reduced weight loss and hypophagia, and increased survival during ABA. Furthermore, amisulpride produced larger reductions in weight loss and hypophagia than olanzapine. Treatment with either D<jats:sub>3<\/jats:sub>receptor antagonist SB277011A or D<jats:sub>2<\/jats:sub>receptor antagonist L-741,626 also increased survival. All the other treatments either had no effect or worsened ABA. Overall, selective antagonism of D<jats:sub>2<\/jats:sub>and\/or D<jats:sub>3<\/jats:sub>receptors robustly reduces ABA. Studies investigating the mechanisms by which D<jats:sub>2<\/jats:sub>and\/or D<jats:sub>3<\/jats:sub>receptors regulate ABA, and the efficacy for D<jats:sub>2\/3<\/jats:sub>and\/or D<jats:sub>3<\/jats:sub>antagonists to treat AN, are warranted.<\/jats:p>","DOI":"10.1038\/tp.2015.109","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T13:42:44Z","timestamp":1438695764000},"page":"e613-e613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Dopamine D2\/3 receptor antagonism reduces activity-based anorexia"],"prefix":"10.1038","volume":"5","author":[{"given":"S J","family":"Klenotich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E V","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"Server","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S C","family":"Dulawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,4]]},"reference":[{"key":"BFtp2015109_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.med.050208.200745","volume":"61","author":"E Attia","year":"2010","unstructured":"Attia E . Anorexia nervosa: current status and future directions. Annu Rev Med 2010; 61: 425\u2013435.","journal-title":"Annu Rev Med"},{"key":"BFtp2015109_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/archpsyc.63.3.305","volume":"63","author":"CM Bulik","year":"2006","unstructured":"Bulik CM, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL . Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry 2006; 63: 305\u2013312.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2015109_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.biopsych.2006.03.040","volume":"61","author":"JI Hudson","year":"2007","unstructured":"Hudson JI, Hiripi E, Pope HG Jr, Kessler RC . The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348\u2013358.","journal-title":"Biol Psychiatry"},{"key":"BFtp2015109_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/eat.22316","volume":"47","author":"FR Smink","year":"2014","unstructured":"Smink FR, van Hoeken D, Oldehinkel AJ, Hoek HW . Prevalence and severity of DSM-5 eating disorders in a community cohort of adolescents. Int J Eat Disord 2014; 47: 610\u2013619.","journal-title":"Int J Eat Disord"},{"key":"BFtp2015109_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archgenpsychiatry.2011.22","volume":"68","author":"SA Swanson","year":"2011","unstructured":"Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR . Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry 2011; 68: 714\u2013723.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2015109_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s11920-012-0282-y","volume":"14","author":"FR Smink","year":"2012","unstructured":"Smink FR, van Hoeken D, Hoek HW . Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep 2012; 14: 406\u2013414.","journal-title":"Curr Psychiatry Rep"},{"key":"BFtp2015109_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.173.1.11","volume":"173","author":"EC Harris","year":"1998","unstructured":"Harris EC, Barraclough B . Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11\u201353.","journal-title":"Br J Psychiatry"},{"key":"BFtp2015109_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1037\/h0060276","volume":"47","author":"JF Hall","year":"1954","unstructured":"Hall JF, Hanford PV . Activity as a function of a restricted feeding schedule. J Comp Physiol Psychol 1954; 47: 362\u2013363.","journal-title":"J Comp Physiol Psychol"},{"key":"BFtp2015109_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1037\/h0025205","volume":"64","author":"A Routtenberg","year":"1967","unstructured":"Routtenberg A, Kuznesof AW . Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol 1967; 64: 414\u2013421.","journal-title":"J Comp Physiol Psychol"},{"key":"BFtp2015109_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/jn\/123.7.1217","volume":"123","author":"VR Burden","year":"1993","unstructured":"Burden VR, White BD, Dean RG, Martin RJ . Activity of the hypothalamic-pituitary-adrenal axis is elevated in rats with activity-based anorexia. J Nutr 1993; 123: 1217\u20131225.","journal-title":"J Nutr"},{"key":"BFtp2015109_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3758\/BF03196278","volume":"9","author":"E Gutierrez","year":"2002","unstructured":"Gutierrez E, Vazquez R, Boakes RA . Activity-based anorexia: ambient temperature has been a neglected factor. Psychon Bull Rev 2002; 9: 239\u2013249.","journal-title":"Psychon Bull Rev"},{"key":"BFtp2015109_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0031-9384(92)90122-I","volume":"51","author":"K Watanabe","year":"1992","unstructured":"Watanabe K, Hara C, Ogawa N . Feeding conditions and estrous cycle of female rats under the activity-stress procedure from aspects of anorexia nervosa. Physiol Behav 1992; 51: 827\u2013832.","journal-title":"Physiol Behav"},{"key":"BFtp2015109_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1037\/0735-7044.113.5.1080","volume":"113","author":"RA Boakes","year":"1999","unstructured":"Boakes RA, Mills KJ, Single JP . Sex differences in the relationship between activity and weight loss in the rat. Behav Neurosci 1999; 113: 1080\u20131089.","journal-title":"Behav Neurosci"},{"key":"BFtp2015109_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/0031-9384(91)90419-O","volume":"50","author":"LE Doerries","year":"1991","unstructured":"Doerries LE, Stanley EZ, Aravich PF . Activity-based anorexia: relationship to gender and activity-stress ulcers. Physiol Behav 1991; 50: 945\u2013949.","journal-title":"Physiol Behav"},{"key":"BFtp2015109_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2466\/pr0.1978.43.2.591","volume":"43","author":"WPVG Par\u00e9","year":"1978","unstructured":"Par\u00e9 WP VG, Isom KE, Reeves JM . Sex differences and incidence of activity-stress ulcers in the rat. Psychol Rep 1978; 43: 591\u2013594.","journal-title":"Psychol Rep"},{"key":"BFtp2015109_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1037\/h0031047","volume":"76","author":"DJ Woods","year":"1971","unstructured":"Woods DJ, Routtenberg A . \u2018Self-starvation\u2019 in activity wheels: developmental and chlorpromazine interactions. J Comp Physiol Psychol 1971; 76: 84\u201393.","journal-title":"J Comp Physiol Psychol"},{"key":"BFtp2015109_CR17","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1017\/S0033291711000390","volume":"41","author":"E Attia","year":"2011","unstructured":"Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41: 2177\u20132182.","journal-title":"Psychol Med"},{"key":"BFtp2015109_CR18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1176\/appi.ajp.2008.07121900","volume":"165","author":"H Bissada","year":"2008","unstructured":"Bissada H, Tasca GA, Barber AM, Bradwejn J . Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281\u20131288.","journal-title":"Am J Psychiatry"},{"key":"BFtp2015109_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/j.1440-1665.2004.02154.x","volume":"13","author":"N Mondraty","year":"2005","unstructured":"Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P . Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005; 13: 72\u201375.","journal-title":"Australas Psychiatry"},{"key":"BFtp2015109_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/YIC.0b013e328080ca31","volume":"22","author":"F Brambilla","year":"2007","unstructured":"Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007; 22: 197\u2013204.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFtp2015109_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/cap.2010.0139","volume":"21","author":"V Kafantaris","year":"2011","unstructured":"Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011; 21: 207\u2013212.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"BFtp2015109_CR22","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/npp.2012.7","volume":"37","author":"SJ Klenotich","year":"2012","unstructured":"Klenotich SJ, Seiglie MP, McMurray MS, Roitman JD, Le Grange D, Dugad P et al. Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice. Neuropsychopharmacology 2012; 37: 1620\u20131631.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015109_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87\u201396.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015109_CR24","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","volume":"32","author":"NM Richtand","year":"2007","unstructured":"Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK . Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007; 32: 1715\u20131726.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015109_CR25","doi-asserted-by":"publisher","first-page":"155S","DOI":"10.1093\/ajcn\/55.1.155s","volume":"55","author":"JE Blundell","year":"1992","unstructured":"Blundell JE . Serotonin and the biology of feeding. Am J Clin Nutr 1992; 55: 155S\u2013159S.","journal-title":"Am J Clin Nutr"},{"key":"BFtp2015109_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tins.2007.06.004","volume":"30","author":"RD Palmiter","year":"2007","unstructured":"Palmiter RD . Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 2007; 30: 375\u2013381.","journal-title":"Trends Neurosci"},{"key":"BFtp2015109_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0028-3908(71)90005-0","volume":"10","author":"HC Fibiger","year":"1971","unstructured":"Fibiger HC, Campbell BA . The effect of para-chlorophenylalanine on spontaneous locomotor activity in the rat. Neuropharmacology 1971; 10: 25\u201332.","journal-title":"Neuropharmacology"},{"key":"BFtp2015109_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0014-2999(76)90299-5","volume":"35","author":"AJ Pijnenburg","year":"1976","unstructured":"Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM . Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 1976; 35: 45\u201358.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/archpsyc.1991.01810300068010","volume":"48","author":"WH Kaye","year":"1991","unstructured":"Kaye WH, Gwirtsman HE, George DT, Ebert MH . Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry 1991; 48: 556\u2013562.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2015109_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0006-3223(88)90113-8","volume":"23","author":"WH Kaye","year":"1988","unstructured":"Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH . CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry 1988; 23: 102\u2013105.","journal-title":"Biol Psychiatry"},{"key":"BFtp2015109_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0893-133X(99)00053-6","volume":"21","author":"WH Kaye","year":"1999","unstructured":"Kaye WH, Frank GK, McConaha C . Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 1999; 21: 503\u2013506.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015109_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.biopsych.2005.05.003","volume":"58","author":"GK Frank","year":"2005","unstructured":"Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC et al. Increased dopamine D2\/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry 2005; 58: 908\u2013912.","journal-title":"Biol Psychiatry"},{"key":"BFtp2015109_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/syn.20421","volume":"61","author":"Y Ago","year":"2007","unstructured":"Ago Y, Nakamura S, Kajita N, Uda M, Hashimoto H, Baba A et al. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 2007; 61: 757\u2013763.","journal-title":"Synapse"},{"key":"BFtp2015109_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0028-3908(93)90110-O","volume":"32","author":"B Gao","year":"1993","unstructured":"Gao B, Cutler MG . Effects of acute and subchronic administration of ritanserin on the social behaviour of mice. Neuropharmacology 1993; 32: 265\u2013272.","journal-title":"Neuropharmacology"},{"key":"BFtp2015109_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2007.02.031","volume":"564","author":"YA Su","year":"2007","unstructured":"Su YA, Si TM, Zhou DF, Guo CM, Wang XD, Yang Y et al. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A\/2C receptors. Eur J Pharmacol 2007; 564: 123\u2013130.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/ALN.0b013e31820efb19","volume":"114","author":"DY Liang","year":"2011","unstructured":"Liang DY, Li X, Clark JD . 5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 2011; 114: 1180\u20131189.","journal-title":"Anesthesiology"},{"key":"BFtp2015109_CR37","first-page":"677","volume":"18","author":"M Roychoudhury","year":"1996","unstructured":"Roychoudhury M, Kulkarni SK . Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist. Methods Find Exp Clin Pharmacol 1996; 18: 677\u2013683.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"BFtp2015109_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nature10899","volume":"483","author":"Q Wu","year":"2012","unstructured":"Wu Q, Clark MS, Palmiter RD . Deciphering a neuronal circuit that mediates appetite. Nature 2012; 483: 594\u2013597.","journal-title":"Nature"},{"key":"BFtp2015109_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0304-3940(03)00637-2","volume":"347","author":"JT Cheng","year":"2003","unstructured":"Cheng JT, Kuo DY . Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. Neurosci Lett 2003; 347: 136\u2013138.","journal-title":"Neurosci Lett"},{"key":"BFtp2015109_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0278-5846(01)00266-4","volume":"26","author":"G Kaur","year":"2002","unstructured":"Kaur G, Kulkarni SK . Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 277\u2013285.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtp2015109_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1472-8206.1991.tb00734.x","volume":"5","author":"N Ladurelle","year":"1991","unstructured":"Ladurelle N, Duterte-Boucher D, Costentin J . Stimulation of D1 and D2 dopamine receptors produces additive anorectic effects. Fundam Clin Pharmacol 1991; 5: 481\u2013490.","journal-title":"Fundam Clin Pharmacol"},{"key":"BFtp2015109_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0748730412455913","volume":"27","author":"YY Liu","year":"2012","unstructured":"Liu YY, Liu TY, Qu WM, Hong ZY, Urade Y, Huang ZL . Dopamine is involved in food-anticipatory activity in mice. J Biol Rhythms 2012; 27: 398\u2013409.","journal-title":"J Biol Rhythms"},{"key":"BFtp2015109_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.alcohol.2011.06.004","volume":"45","author":"ZB Bulwa","year":"2011","unstructured":"Bulwa ZB, Sharlin JA, Clark PJ, Bhattacharya TK, Kilby CN, Wang Y et al. Increased consumption of ethanol and sugar water in mice lacking the dopamine D2 long receptor. Alcohol 2011; 45: 631\u2013639.","journal-title":"Alcohol"},{"key":"BFtp2015109_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s002130000668","volume":"155","author":"AL Chausmer","year":"2001","unstructured":"Chausmer AL, Katz JL . The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharmacology 2001; 155: 69\u201377.","journal-title":"Psychopharmacology"},{"key":"BFtp2015109_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/026988119701100409","volume":"11","author":"F Ferrari","year":"1997","unstructured":"Ferrari F, Giuliani D . Effects of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice. J Psychopharmacol 1997; 11: 339\u2013344.","journal-title":"J Psychopharmacol"},{"key":"BFtp2015109_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2005.06.006","volume":"135","author":"L Cordonnier","year":"2005","unstructured":"Cordonnier L, Sanchez M, Roques BP, Noble F . Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 2005; 135: 1\u201310.","journal-title":"Neuroscience"},{"key":"BFtp2015109_CR47","first-page":"327","volume":"66","author":"GR Pawar","year":"2009","unstructured":"Pawar GR, Agrawal RP, Phadnis P, Paliwal A, Vyas S, Solanki P . Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm 2009; 66: 327\u2013331.","journal-title":"Acta Pol Pharm"},{"key":"BFtp2015109_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B . Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtp2015109_CR49","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","volume":"12","author":"B Scatton","year":"1997","unstructured":"Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997; 12: S29\u2013S36.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFtp2015109_CR50","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/jpet.106.110684","volume":"320","author":"A Bespalov","year":"2007","unstructured":"Bespalov A, Jongen-Relo AL, van Gaalen M, Harich S, Schoemaker H, Gross G . Habituation deficits induced by metabotropic glutamate receptors 2\/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 2007; 320: 944\u2013950.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtp2015109_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/01.fbp.0000137857.26150.ab","volume":"15","author":"I Gyertyan","year":"2004","unstructured":"Gyertyan I, Saghy K . Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol 2004; 15: 253\u2013262.","journal-title":"Behav Pharmacol"},{"key":"BFtp2015109_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1369-1600.2007.00051.x","volume":"12","author":"CA Heidbreder","year":"2007","unstructured":"Heidbreder CA, Andreoli M, Marcon C, Hutcheson DM, Gardner EL, Ashby CR Jr . Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007; 12: 35\u201350.","journal-title":"Addict Biol"},{"key":"BFtp2015109_CR53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","volume":"294","author":"C Reavill","year":"2000","unstructured":"Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000; 294: 1154\u20131165.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtp2015109_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nbd.2009.10.009","volume":"37","author":"X Fan","year":"2010","unstructured":"Fan X, Xu M, Hess EJ . D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD. Neurobiol Dis 2010; 37: 228\u2013236.","journal-title":"Neurobiol Dis"},{"key":"BFtp2015109_CR55","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(24)39333-4","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M . S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1063\u20131073.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtp2015109_CR56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.bbr.2010.06.005","volume":"214","author":"H Onogi","year":"2010","unstructured":"Onogi H, Nakagawasai O, Tan-No K, Mitazaki S, Sato A, Nakaya K et al. p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission. Behav Brain Res 2010; 214: 349\u2013356.","journal-title":"Behav Brain Res"},{"key":"BFtp2015109_CR57","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1172\/JCI61888","volume":"122","author":"TT Riday","year":"2012","unstructured":"Riday TT, Dankoski EC, Krouse MC, Fish EW, Walsh PL, Han JE et al. Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. J Clin Invest 2012; 122: 4544\u20134554.","journal-title":"J Clin Invest"},{"key":"BFtp2015109_CR58","first-page":"187","volume-title":"Handbook of Experimental Pharmacology","author":"MA Geyer","year":"2012","unstructured":"Geyer MA, Gross G . Novel antischizophrenia treatments. Handbook of Experimental Pharmacology. Springer: Heidelberg, Germany\/New York, NY, USA, 2012, pp 187."},{"key":"BFtp2015109_CR59","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejphar.2007.06.035","volume":"572","author":"I Gyertyan","year":"2007","unstructured":"Gyertyan I, Saghy K . The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007; 572: 171\u2013174.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR60","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/S0014-2999(97)00049-6","volume":"321","author":"MJ Millan","year":"1997","unstructured":"Millan MJ, Gressier H, Brocco M . The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 1997; 321: R7\u2013R9.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR61","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1038\/srep03929","volume":"4","author":"H Wu","year":"2014","unstructured":"Wu H, van Kuyck K, Tambuyzer T, Luyten L, Aerts JM, Nuttin B . Rethinking food anticipatory activity in the activity-based anorexia rat model. Sci Rep 2014; 4: 3929.","journal-title":"Sci Rep"},{"key":"BFtp2015109_CR62","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.pbb.2006.03.016","volume":"83","author":"DP Atchley","year":"2006","unstructured":"Atchley DP, Eckel LA . Treatment with 8-OH-DPAT attenuates the weight loss associated with activity-based anorexia in female rats. Pharmacol Biochem Behav 2006; 83: 547\u2013553.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015109_CR63","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.biopsych.2005.04.008","volume":"58","author":"JJ Hillebrand","year":"2005","unstructured":"Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA . Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 2005; 58: 651\u2013657.","journal-title":"Biol Psychiatry"},{"key":"BFtp2015109_CR64","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","volume":"25","author":"JL Roerig","year":"2011","unstructured":"Roerig JL, Steffen KJ, Mitchell JE . Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035\u20131059.","journal-title":"CNS Drugs"},{"key":"BFtp2015109_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF00177567","volume":"96","author":"PJ Fletcher","year":"1988","unstructured":"Fletcher PJ . Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacology 1988; 96: 237\u2013242.","journal-title":"Psychopharmacology"},{"key":"BFtp2015109_CR66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0014-2999(92)90346-6","volume":"212","author":"G Grignaschi","year":"1992","unstructured":"Grignaschi G, Samanin R . Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur J Pharmacol 1992; 212: 287\u2013289.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0091-3057(87)90127-4","volume":"26","author":"M Massi","year":"1987","unstructured":"Massi M, Marini S . Effect of the 5HT2 antagonist ritanserin on food intake and on 5HT-induced anorexia in the rat. Pharmacol Biochem Behav 1987; 26: 333\u2013340.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015109_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0028-3908(89)90080-4","volume":"28","author":"R Samanin","year":"1989","unstructured":"Samanin R, Mennini T, Bendotti C, Barone D, Caccia S, Garattini S . Evidence that central 5-HT2 receptors do not play an important role in the anorectic activity of D-fenfluramine in the rat. Neuropharmacology 1989; 28: 465\u2013469.","journal-title":"Neuropharmacology"},{"key":"BFtp2015109_CR69","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0091-3057(02)01029-8","volume":"74","author":"C von Meyenburg","year":"2003","unstructured":"von Meyenburg C, Langhans W, Hrupka BJ . Evidence that the anorexia induced by lipopolysaccharide is mediated by the 5-HT2C receptor. Pharmacol Biochem Behav 2003; 74: 505\u2013512.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015109_CR70","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0140-6736(99)09062-5","volume":"355","author":"PL Faris","year":"2000","unstructured":"Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355: 792\u2013797.","journal-title":"Lancet"},{"key":"BFtp2015109_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/hup.1145","volume":"25","author":"F Soltani","year":"2010","unstructured":"Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I . A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 2010; 25: 509\u2013513.","journal-title":"Hum Psychopharmacol"},{"key":"BFtp2015109_CR72","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1176\/appi.ajp.161.12.2215","volume":"161","author":"WH Kaye","year":"2004","unstructured":"Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K . Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 2004; 161: 2215\u20132221.","journal-title":"Am J Psychiatry"},{"key":"BFtp2015109_CR73","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1124\/mol.64.6.1295","volume":"64","author":"WD Hirst","year":"2003","unstructured":"Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003; 64: 1295\u20131308.","journal-title":"Mol Pharmacol"},{"key":"BFtp2015109_CR74","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ejphar.2014.06.011","volume":"740","author":"N Davoodi","year":"2014","unstructured":"Davoodi N, te Riele P, Langlois X . Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain. Eur J Pharmacol 2014; 740: 669\u2013675.","journal-title":"Eur J Pharmacol"},{"key":"BFtp2015109_CR75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/bmj.2.5517.793","volume":"2","author":"P Dally","year":"1966","unstructured":"Dally P, Sargant W . Treatment and outcome of anorexia nervosa. Br Med J 1966; 2: 793\u2013795.","journal-title":"Br Med J"},{"key":"BFtp2015109_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1600-0447.1982.tb04501.x","volume":"66","author":"W Vandereycken","year":"1982","unstructured":"Vandereycken W, Pierloot R . Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982; 66: 445\u2013450.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtp2015109_CR77","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY . Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013; 64: 393\u2013406.","journal-title":"Annu Rev Med"},{"key":"BFtp2015109_CR78","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0278-5846(01)00174-9","volume":"25","author":"GM Ruggiero","year":"2001","unstructured":"Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1049\u20131059.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtp2015109_CR79","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1192\/bjp.144.3.288","volume":"144","author":"W Vandereycken","year":"1984","unstructured":"Vandereycken W . Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984; 144: 288\u2013292.","journal-title":"Br J Psychiatry"},{"key":"BFtp2015109_CR80","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","volume":"160","author":"RA Bressan","year":"2003","unstructured":"Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ et al. Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413\u20131420.","journal-title":"Am J Psychiatry"},{"key":"BFtp2015109_CR81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"280","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtp2015109_CR82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL . Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 2009; 205: 119\u2013128.","journal-title":"Psychopharmacology"},{"key":"BFtp2015109_CR83","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA . Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27\u201335.","journal-title":"Mol Psychiatry"},{"key":"BFtp2015109_CR84","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","volume":"20","author":"EV Gurevich","year":"1999","unstructured":"Gurevich EV, Joyce JN . Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999; 20: 60\u201380.","journal-title":"Neuropsychopharmacology"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp2015109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T21:39:02Z","timestamp":1748554742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp2015109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,4]]},"references-count":84,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["BFtp2015109"],"URL":"https:\/\/doi.org\/10.1038\/tp.2015.109","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,4]]},"assertion":[{"value":"5 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}